Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to $1.4 million.

  • Medifast's Capital Expenditures fell 4087.53% to $1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 million, marking a year-over-year decrease of 2468.47%. This contributed to the annual value of $5.6 million for FY2025, which is 2468.47% down from last year.
  • Medifast's Capital Expenditures amounted to $1.4 million in Q4 2025, which was down 4087.53% from $1.4 million recorded in Q3 2025.
  • Medifast's 5-year Capital Expenditures high stood at $11.6 million for Q4 2021, and its period low was $946000.0 during Q4 2023.
  • Its 5-year average for Capital Expenditures is $3.5 million, with a median of $1.9 million in 2024.
  • In the last 5 years, Medifast's Capital Expenditures skyrocketed by 252906.57% in 2021 and then crashed by 8956.31% in 2023.
  • Medifast's Capital Expenditures (Quarter) stood at $11.6 million in 2021, then dropped by 22.02% to $9.1 million in 2022, then tumbled by 89.56% to $946000.0 in 2023, then soared by 141.54% to $2.3 million in 2024, then tumbled by 40.88% to $1.4 million in 2025.
  • Its Capital Expenditures was $1.4 million in Q4 2025, compared to $1.4 million in Q3 2025 and $1.4 million in Q2 2025.